Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 12

A personalized approach to acute myeloid leukemia therapy: current options

Authors Illangeswaran RSS, Das S, Paul DZ, Mathews V, Balasubramanian P

Received 25 March 2019

Accepted for publication 10 July 2019

Published 2 August 2019 Volume 2019:12 Pages 167—179

DOI https://doi.org/10.2147/PGPM.S168267

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Martin Bluth


Raveen Stephen Stallon Illangeswaran, Saswati Das, Daniel Zechariah Paul, Vikram Mathews, Poonkuzhali Balasubramanian

Department of Haematology, Christian Medical College, Vellore, India

Abstract: Therapeutic options for acute myeloid leukemia (AML) have remained unchanged for nearly the past 5 decades, with cytarabine and anthracyclines and use of hypomethylating agents for less intensive therapy. Implementation of large-scale genomic studies in the past decade has unraveled the genetic landscape and molecular etiology of AML. The approval of several novel drugs for targeted therapy, including midostaurin, enasidenib, ivosidenib, gemtuzumab–ozogamicin, and CPX351 by the US Food and Drug Administration has widened the treatment options for clinicians treating AML. This review focuses on some of these novel therapies and other promising agents under development, along with key clinical trial findings in AML.

Keywords: acute myeloid leukemia, personalized medicine, chemotherapy, molecular markers


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]